Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
 
Status Schedule affected by COVID-19
Process CDF Review
ID number 1585

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Bristol-Myers Squibb (nivolumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (docetaxel, methotrexate) - not participating, CAU not returned
  Actavis UK (docetaxel) - not participating, CAU not returned
  Dr. Reddy's Laboratories (docetaxel) - not participating, CAU not returned
  Hospira UK (docetaxel, methotrexate) - not participating, CAU not returned
  Medac GmbH (docetaxel) - not participating, CAU not returned
  Pfizer (methotrexate)
  Sanofi (docetaxel)
  Teva UK (docetaxel) - not participating, CAU not returned
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Medicines and Healthcare products Regulatory Agency
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
04 June 2020 Committee meeting
05 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
06 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
30 January 2020 Invitation to participate
24 January 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance